SCD-044 Tablets 0.3mg

DRUG2 trials

Sponsors

Sun Pharmaceutical Industries Limited

Conditions

atopic dermatitismoderate to severe plaque psoriasis

Phase 2

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis

CompletedCTIS2023-506477-35-00

Sun Pharmaceutical Industries Limitedmoderate to severe plaque psoriasis

Start: 2024-04-02End: 2025-08-27Target: 63Updated: 2024-10-23

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SCD-044 IN THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS

CompletedCTIS2024-511615-16-00

Sun Pharmaceutical Industries Limitedatopic dermatitis

Start: 2023-08-25End: 2024-11-25Target: 43Updated: 2024-10-24